Global Breath Analyzers Market Strategic Research Report

Scope of the Report

The global Breath Analyzers market size is predicted to grow from US$ 299 million in 2025 to US$ 634 million in 2032; it is expected to grow at a CAGR of 11.5% from 2026 to 2032.

Breath Molecular Diagnosis is a medical diagnosis based on the detection of the molecular composition of exhaled breath, also referred to as Breath Diagnosis or Breath Test. Medical diagnosis based on the detection of exhaled flow pressure is called Pulmonary Function Test, which is also a type of exhaled test or exhaled diagnosis. To avoid confusion, the issuer mainly uses the name "exhaled molecular diagnosis", but sometimes for the sake of simplicity and consistency with the name of the outside world, the name "exhaled diagnosis" or "exhaled test" is also used. Exhaled molecular diagnosis is an emerging in vitro diagnostic (IVD) technology. Generally speaking, in vitro diagnosis requires the use of diagnostic reagents and equipment to analyze samples such as blood or urine. Sampling is performed first and then analysis. Cells, microorganisms and biochemical molecules can be analyzed. It is mainly used for the diagnosis of blood circulation or systemic diseases. Exhaled molecular diagnosis does not require diagnostic reagents, and sampling and analysis can be performed at the same time. It analyzes gas molecules produced by cell and microbial metabolism, which is particularly suitable for the diagnosis of respiratory and digestive related diseases. The role of exhaled breath molecular diagnosis is complementary to that of blood tests and imaging diagnosis. Like existing in vitro diagnostics, exhaled breath molecular diagnosis is also divided into two categories: professional laboratories and point-of-care diagnostics (POCT). Professional laboratories use laboratory analytical equipment such as gas chromatography, mass spectrometry and spectroscopy to perform exhaled breath analysis on patients' exhaled breath bags or gas collection tubes; due to the lack of exhaled breath sensor products, Europe and the United States currently provide analytical services for H2, CH4 and VOC (volatile organic compounds) exhaled breath metabolomics through professional laboratories. Point-of-care diagnostics (POCT) use exhaled breath detection sensors, which integrate sampling and analysis. Patients only need a few seconds to sample their breath, and the instrument only needs tens of seconds to analyze the results. In summary, the issuer belongs to the POCT sub-industry in the emerging IVD field. Exhaled breath molecular diagnostic equipment is classified as a low-risk medical device by European and American drug regulatory authorities. The U.S. FDA believes that exhaled breath testing will affect medical diagnostic results. As a Class II medical device, it only tests and certifies the performance of exhaled breath testing. The EU regulates it as a special Class I medical device similar to a sphygmomanometer, which only requires self-testing or third-party laboratory testing according to EN standards. Therefore, exhaled breath molecular diagnostic equipment was first launched in Europe, and there are many of them now. China currently regulates exhaled breath molecular diagnostic equipment as Class II medical devices, and registration takes a long time. At present, most medical devices related to exhaled breath molecular diagnostic technology are in the market cultivation or introduction stage, requiring a large number of clinical trials, certification and registration.

POCT based on exhaled breath molecular diagnosis can provide detection items that blood test POCT lacks, such as detection of airway inflammation and gastrointestinal flora metabolic disorders. Moreover, POCT based on exhaled breath molecular diagnosis does not require blood drawing, and has the characteristics of non-invasive, instant, and biopsy. It can be used to make up for the shortcomings of in vitro diagnosis such as blood tests and imaging, avoid the risks of invasive in vivo diagnosis, and is more suitable for the use of common diseases and chronic diseases in hospitals, grassroots physical examinations, and family self-examination. In recent years, exhaled breath molecular diagnosis technology has been increasingly valued by domestic and foreign governments, research and development institutions, and related medical organizations. Various organizations and institutions have formulated relevant policies, development plans, and standard guidelines to jointly promote the rapid development of clinical technology for exhaled breath molecular diagnosis.

Exhaled breath molecular diagnosis or breath testing belongs to the emerging field of POCT technology. At present, the Helicobacter pylori breath test with the largest market size has a market history of less than 25 years, and the development of the inflammatory breath test product with the greatest market potential has only been 10 years, while breath testing technologies such as gastrointestinal flora metabolic disorders are still in the market cultivation stage. In addition, breath detection technologies such as breath NH3, H2S, VOC (volatile organic compounds), breath metabolomics and olfactory artificial intelligence (electronic nose) are still in clinical trials or waiting for drug regulatory certification and approval.

In the past 30 years, with the gradual development of related technologies including breath detection abroad, the rapid growth of the domestic economy and the continuous development of the medical and health industry have provided a broad market space for the widespread application of this technology in China. At the same time, the development of domestic breath detection technology is almost synchronized with that of foreign countries, covering almost all areas of foreign breath detection, including the research of breath metabolomics and olfactory artificial intelligence, and many technologies are even ahead of foreign countries. It is one of the few emerging technology fields that may form a global leading breath detection in China.

With the continuous advancement of the construction of the PCCM system, the demand for breath analysis products in secondary and tertiary hospitals will further expand. Portable instrument products, handheld instrument products and other products for primary hospitals and home terminals are constantly being developed, and product application scenarios and usage needs will be further expanded.

With the development of science and technology and artificial intelligence, future breathalyzers will be more intelligent and automated, with functions such as automatic identification, data analysis and report generation, reducing human intervention and improving diagnostic accuracy and efficiency.

This report presents a comprehensive overview of the global Breath Analyzers market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• C13 Type
• NO Type
• H2/CO Type
• VOCs Type

Segment by Application

• Hospital
• Clinic
• Physical Examination Center
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Breath Analyzers market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospital, Clinic, Physical Examination Center evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact